19 Jul Garuda Therapeutics
Dhvanit Shah, Ph.D., President and CEO
Oct. 11 | 4:15pm | Rentschler ATMP Ballroom
Our platform technology for generating self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. As the industry’s first off-the-shelf offering, Garuda’s technology has the potential to cure more than 70 diseases and eliminate dependency on donor or patient cells.